원료의약품(API) 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 합성 유형별, 용도별, 지역별, 경쟁별(2020-2030년)

The Global Active Pharmaceutical Ingredient (API) Market was valued at USD 155.41 Billion in 2024 and is projected to reach USD 227.67 Billion by 2030, growing at a CAGR of 6.77% during the forecast period. Demand for APIs is rising steadily as pharmaceutical companies broaden their therapeutic portfolios to address a wide array of conditions including oncology, cardiovascular ailments, neurological disorders, diabetes, and respiratory diseases. This surge is largely driven by the growing global burden of chronic illnesses, an aging population, and evolving lifestyle factors.

The market landscape is being shaped by increasing regulatory scrutiny focused on Good Manufacturing Practices (GMP) and stringent quality control standards. API manufacturers are responding by investing in advanced technologies, improving process automation, and prioritizing environmental sustainability. As global supply chains continue to diversify, strategic investment in regulatory compliance, infrastructure, and geographic resilience will remain essential for manufacturers seeking to maintain competitiveness and meet the dynamic needs of the pharmaceutical sector.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare sector is a primary catalyst for growth in the API market. With healthcare spending exceeding USD 4 trillion annually, pharmaceuticals and biotechnology account for a significant portion-over USD 850 billion-underscoring the vital role APIs play in medical innovation and treatment delivery.

The escalating prevalence of chronic conditions such as cardiovascular diseases, cancer, and diabetes has led to a sharp increase in demand for high-quality, effective APIs. In 2021, noncommunicable diseases (NCDs) accounted for around 43 million deaths worldwide, representing approximately 75% of all non-pandemic-related fatalities. These health burdens drive the need for long-term medication use, prompting pharmaceutical companies to ramp up API production to meet growing therapeutic demands. The development of biologics and high-potency APIs (HPAPIs) further reflects the healthcare sector's focus on targeted, personalized treatments, reinforcing sustained market growth.

Key Market Challenges

High Cost of Production

High production costs present a substantial barrier in the global API market, affecting both manufacturer margins and the affordability of end products. These costs stem from intricate synthesis procedures, rigorous quality and safety requirements, and the rising expense of sourcing raw materials.

Complying with Good Manufacturing Practices (GMP) mandates the use of highly specialized equipment, skilled personnel, and continuous quality assurance efforts, significantly elevating both capital and operational expenditures-particularly in developed markets. Additionally, maintaining consistent output quality, ensuring regulatory compliance, and managing environmentally sustainable operations add further financial strain. This economic burden restricts entry for smaller firms and contributes to price volatility, especially in regions with limited manufacturing infrastructure.

Key Market Trends

Rise of Peptide and Oligonucleotide APIs

A prominent trend shaping the API market is the surge in demand for peptide and oligonucleotide APIs, driven by the global push toward precision medicine and biologically targeted therapies. GLP-1 analogs like semaglutide and liraglutide are gaining attention in the generics segment, particularly for their effectiveness in treating diabetes and obesity.

Peptides, with their high specificity and minimal toxicity, are increasingly used in treating cancers and metabolic or rare genetic disorders. Likewise, oligonucleotide APIs, composed of DNA or RNA sequences, allow for therapeutic targeting at the genetic level, opening new treatment avenues for diseases previously considered intractable. These innovations support the pharmaceutical industry's pivot to high-efficacy treatments, marking a shift from conventional small-molecule drugs to advanced, biologically complex APIs.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH
• Merck & Co., Inc.
• GlaxoSmithKline Plc
• Novartis International AG
• F. Hoffmann-La Roche AG
• Sanofi S.A.
• Eli Lilly and Company
• AbbVie Inc

Report Scope

In this report, the Global Active Pharmaceutical Ingredient Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredient Market, By Type of Synthesis:

• Biotech
• Fermentation
• Plant Extracts
• Synthetic

Active Pharmaceutical Ingredient Market, By Application:

• Cardiovascular Disease
• Oncology
• Neurological Disorders
• Orthopedic Disorders
• Respiratory
• Gastrointestinal Disorders
• Urology
• Others

Active Pharmaceutical Ingredient Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredient Market.

Available Customizations

Global Active Pharmaceutical Ingredient Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Active Pharmaceutical Ingredient Market

5. Global Active Pharmaceutical Ingredient Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Synthesis (Biotech, Fermentation, Plant Extracts, Synthetic)
  • 5.2.2. By Application (Cardiovascular Disease, Oncology, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Active Pharmaceutical Ingredient Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Synthesis
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Active Pharmaceutical Ingredient Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Synthesis
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Active Pharmaceutical Ingredient Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Synthesis
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Active Pharmaceutical Ingredient Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Synthesis
      • 6.3.3.2.2. By Application

7. Europe Active Pharmaceutical Ingredient Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Synthesis
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Active Pharmaceutical Ingredient Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Synthesis
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Active Pharmaceutical Ingredient Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Synthesis
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Active Pharmaceutical Ingredient Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Synthesis
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Active Pharmaceutical Ingredient Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Synthesis
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Active Pharmaceutical Ingredient Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Synthesis
      • 7.3.5.2.2. By Application

8. Asia Pacific Active Pharmaceutical Ingredient Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Synthesis
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Active Pharmaceutical Ingredient Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Synthesis
      • 8.3.1.2.2. By Application
  • 8.3.2. India Active Pharmaceutical Ingredient Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Synthesis
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Active Pharmaceutical Ingredient Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Synthesis
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Active Pharmaceutical Ingredient Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Synthesis
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Active Pharmaceutical Ingredient Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Synthesis
      • 8.3.5.2.2. By Application

9. South America Active Pharmaceutical Ingredient Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Synthesis
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Active Pharmaceutical Ingredient Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Synthesis
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Active Pharmaceutical Ingredient Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Synthesis
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Active Pharmaceutical Ingredient Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Synthesis
      • 9.3.3.2.2. By Application

10. Middle East and Africa Active Pharmaceutical Ingredient Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Synthesis
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Active Pharmaceutical Ingredient Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Synthesis
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Active Pharmaceutical Ingredient Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Synthesis
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Active Pharmaceutical Ingredient Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Synthesis
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Active Pharmaceutical Ingredient Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Teva Pharmaceutical Industries Ltd.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Bristol-Myers Squibb Company
• 16.3. Boehringer Ingelheim GmbH
• 16.4. Merck & Co., Inc.
• 16.5. GlaxoSmithKline Plc
• 16.6. Novartis International AG
• 16.7. F. Hoffmann-La Roche AG
• 16.8. Sanofi S.A.
• 16.9. Eli Lilly and Company
• 16.10. AbbVie Inc

17. Strategic Recommendations

18. About Us & Disclaimer